From Patient
to possibility
Restoring hope through a fundamentally new approach to treating stroke and neurodegenerative diseases
Revalesio is a clinical-stage pharmaceutical company with a vision to develop safer and more effective treatments for people with an acute ischemic stroke and other neurological conditions. Our pioneering science addresses fundamental disease mechanisms to improve recovery and reduce disability in stroke and slow disease progression in chronic neurological conditions, aiming to make meaningful improvements in the quality of life of individuals who currently have few therapeutic treatment options.
Promising
Pipeline
Our lead candidate, RNS60, is rapidly advancing in clinical programs in ischemic stroke and amyotrophic lateral sclerosis (ALS)
Unique
Technology
Our proprietary technology applies physics to create a new class of drugs
Career
Opportunities
Join us in our effort to improve the lives of millions